Future of Cardiovascular Diagnostics: Impact of Technological Advances on Growth Opportunities and Market Outlook

Introduction

The report analyzes a variety of cardiac biomarkers currently on the market, including those used to determine cholesterol and lipoprotein levels, cardiac necrosis, thrombosis, inflammation and genetic variants. Furthermore, a large number of biomarkers are currently under evaluation, and if successful, may provide cardiologists with a more comprehensive assessment of cardiovascular risk and prognosis.

Scope

- Analyzes key IVD and imaging technologies, and their applications for early diagnosis, treatment and patient monitoring in CVD.
- Assesses current approaches being adopted by the leading IVD and emerging market entrants.
- Profiles leading companies developing novel technologies for IVD and diagnostic imaging.
- Analyses potential of products and technologies for improving diagnosis and guiding treatment decisions earlier during the course of CVD.
- Reviews benefits associated with different approaches to IVD and diagnostic imaging.

Research and analysis highlights

Increasingly, IVD testing is being used by cardiologists in conjunction with diagnostic imaging to stratify patient risk, improve diagnosis, minimize the use of invasive procedures and improve patient management. Several tests are now available that can indentify asymptomatic patients that are at high risk of CV disease, allowing for early dietary and lifestyle interventions and the prescription of preventative medicine if necessary. Extensive research indicates that the application of IVD and diagnostic imaging in cardiovascular disease may lead to significant reductions in healthcare costs by increasing the speed of diagnosis, avoiding the need for expensive treatments and reducing mortality rates through early screening programs.

Key reasons to purchase this research

- Discover the reasons for the increasing usage of IVD and diagnostic imaging modalities in recent years.
- Identify the technologies at the forefront of cardiovascular IVD and diagnostic imaging.
- Assess the IVD and healthcare industry's responses to the demands of cardiologists and radiologists.
- Examine the strategies that the leading IVD and healthcare companies use in order to remain ahead in the CV diagnostics field.
# Table of Contents

Cardiovascular Diagnostics
- Executive Summary 10
- Cardiovascular disease & diagnostics 10
- Current cardiac diagnostic modalities 11
- Novel cardiac diagnostic modalities 12
- The market, trends & future directions 13

Chapter 1 Cardiovascular disease & diagnostics 16
- Introduction 17
- Cardiovascular disease 20
- Cardiovascular risk factors 23
- Diagnosis of cardiovascular diseases 25
- Cardiovascular screening 25
- Conclusions on CVD diagnosis and screening 27

Cardiovascular diagnostics 28
- Cardiovascular in vitro diagnostics: biomarkers and tests 28
  - Cholesterol testing 28
  - Lipoprotein & apolipoprotein profiling 30
  - Cholesterol guidelines 31
  - Case study: Atherotech VAP technology 32
- Cardiac biomarkers 34

Chapter 2 Current cardiac diagnostic modalities 44
- Introduction 45
- Coronary artery disease diagnostic tests 46
  - In vitro diagnosis of CAD 46
  - In vivo diagnosis of CAD 49
- Conclusions on diagnostic tests for CAD 54
  - Acute coronary syndromes diagnostics 55
  - In vitro diagnosis for ACS 56
  - In vivo diagnosis of ACS 59
- Conclusions on diagnostic tests for heart attack patients 62
  - Heart failure 62
  - In vitro diagnosis of heart failure 64
  - In vivo diagnosis of heart failure 65
- Conclusion on diagnostic tests for CHF 68
- Stroke 68
Figure 2.16: MUGA scan of the heart 67
Figure 2.17: Doppler Ultrasound in a) normal & b) stroke 69
Figure 2.18: MRI scan of brain following a stroke 70
Figure 2.19: Commercial MRI Units 71
Figure 2.20: Increased risk of stroke with elevated Lp-PLA2 (ARIC Study) 72
Figure 2.21: Roche’s PoC CARDIAC D-Dimer test 75
Figure 2.22: Ventilation-perfusion scan for detecting PEs 76
Figure 2.23: Contrast enhanced CT image of PE 77
Figure 3.24: Global Population (2008) 91
Figure 3.25: Schematic of MPI technology 111
Figure 4.26: The IVD market – geographic split (2008) 119
Figure 4.27: The IVD market – segments (2008) 120
Figure 4.28: The IVD market – market leaders (2008) 121
Figure 4.29: Cardiovascular Diagnostics – Market Segments (2008) 124
Figure 4.30: Leading diagnostic imaging companies (2008) 129
Figure 4.31: Leading diagnostic imaging – market segments (2008) 130
List of Tables
Table 1.1: CVD – conditions & associated risk factors 20
Table 1.2: CVD – conditions & associated risk factors (continued) 21
Table 1.3: Uncontrollable cardiovascular risk factors 23
Table 1.4: Protective cardiovascular risk factors 23
Table 1.5: Controllable / treatable cardiovascular risk factors 24
Table 1.6: ATPIII Classification of TC, LDL-C & HDL-C 32
Table 1.7: Commercially available cardiovascular diagnostics to assess acute coronary syndromes 34
Table 1.8: Commercially available diagnostics to assess cardiovascular risk, stroke & thrombosis 35
Table 1.9: Anatomical - In vivo imaging modalities 36
Table 1.10: Functional - In vivo imaging modalities 37
Table 1.11: Advantages & disadvantages of cardiac imaging modalities 38
Table 1.12: In vivo imaging tests to assess cardiac anatomy & function 39
Table 2.13: Diagnostic tests - CAD 46
Table 2.14: Diagnostics for ACS 55
Table 2.15: Diagnostic tests for heart failure 64
Table 2.16: Properties of BNP 64
Table 2.17: Leading diagnostics for stroke 68
Table 2.18: Leading thrombotic diagnostic tests 74
Table 3.19: COACH trial data on Galectin-3 95
Table 3.20: Commercially available POC cardiac tests 106
Table 4.21: Medical Device Manufacturers & Suppliers in IVD 122
Table 4.22: Medical Device Manufacturers & Suppliers in IVD (continued) 123
Table 4.23: Cardiovascular focused IVD companies 126
Table 4.24 Cardiovascular focused IVD companies (continued): 127
Table 4.25: Medical device manufacturers & suppliers in imaging 131
Table 4.26: Recent M&A activity in the cardiovascular diagnostic arena 142
Table 4.27: Recent M&A activity in the cardiovascular diagnostic arena (continued) 143
Table 4.28: Recent M&A activity in the cardiovascular diagnostic arena (continued) 144
Table 4.29: Recent collaborations in the cardiovascular arena 146
Table 4.30: Recent collaborations in the cardiovascular diagnostic arena (continued) 147
Table 4.31: Recent product launches in cardiovascular IVDs 148

Table 4.32: Recent product launches in diagnostic imaging 151